Search | Clinical Trials Finder

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Prednisone; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 174
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 129 more

Conditions: Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions: MRI IMAGING; Diagnostic Test
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: Experimental: Mentored Gardening Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Peripheral Nervous System Diseases, Testicular Neoplasms
Interventions: Blood sample collection, Report of peripheral neuropathy after cisplatin therapy; Procedure · Behavioral
Lead sponsor: Costantine Albany; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Recurrent Prostate Cancer After Surgery
Interventions: Daily-adaptive Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions: vorinostat (suberoylanilide hydroxamic acid), docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: No intervention; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more

Conditions: BRCA1 Mutation, BRCA2 Mutation
Interventions: Web + Streamlined Telephone Genetic Information; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania

Conditions: Prostate Cancer
Interventions: Internet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration, Laboratory Biomarker Analysis; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Cleveland, Ohio + 1 more

Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions: Olaparib, LHRH agonist; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: La Jolla, California • Baltimore, Maryland • New York, New York + 2 more

Conditions: Prostate Cancer
Interventions: Access needle; Procedure
Lead sponsor: Perineologic; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Cumberland, Maryland

Conditions: Prostate Cancer
Interventions: Radiation; Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Carcinoma
Interventions: Yoga; Other
Lead sponsor: Emory University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Recurrent Prostate Carcinoma
Interventions: Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography; Other · Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Prostate Cancer
Interventions: Brachytherapy, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine, varenicline, placebo; Drug · Other
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Metastatic Prostate Cancer
Interventions: [89Zr]Df-IAB2M; Biological
Lead sponsor: ImaginAb, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: C11-Sodium Acetate; Drug
Lead sponsor: Phoenix Molecular Imaging; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: TAS3681; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 11
States / cities: Sacramento, California • Sarasota, Florida • Tampa, Florida + 8 more

Conditions: Prostate Cancer Metastatic
Interventions: REGN2810, Degarelix, Leuprolide Acetate, Docetaxel; Drug
Lead sponsor: Mark Stein; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Advanced Prostate Carcinoma
Interventions: Participant Surveys, Mobile app; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Degarelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Homewood, Alabama • Laguna Woods, California • Aventura, Florida + 8 more

Conditions: Metastasis From Malignant Tumor of Prostate
Interventions: 177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more

Conditions: Prostate Cancer
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years to 90 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Charleston, South Carolina

Search by objective public record fields.

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Serial MRI Scans During Radiation Therapy

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

A Registry for Patients Treated on the Clinical Trial TAX 3503

Genetic Education in BRCA Families

Decision Aids to Improve Knowledge in Patients With Prostate Cancer

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Prostate Biopsy Access Needle & Needle Guide Feasibility Study

Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer

Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

Brachytherapy for Prostatic Carcinoma Patients

Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial